Lyell Immunopharma Files 8-K
Ticker: LYEL · Form: 8-K · Filed: May 28, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Lyell Immunopharma filed an 8-K on 5/27, expect updates on rights and financials.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on May 28, 2025, reporting a material modification to the rights of security holders and financial statements/exhibits. The filing date is May 27, 2025. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Why It Matters
This 8-K filing indicates significant updates regarding Lyell Immunopharma's corporate structure or financial reporting, which could impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — This is a routine filing to report material modifications and financial statements, not indicative of immediate operational or financial distress.
Key Numbers
- 001-40502 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1300510 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific material modifications to the rights of security holders are being reported?
The filing does not specify the exact nature of the material modifications to the rights of security holders, only that such modifications are being reported.
What financial statements and exhibits are included in this filing?
The filing indicates that financial statements and exhibits are being provided, but the specific details of these documents are not listed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 27, 2025.
What is Lyell Immunopharma, Inc.'s principal executive office address?
Lyell Immunopharma, Inc.'s principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
What is the SIC code for Lyell Immunopharma, Inc.?
The Standard Industrial Classification (SIC) code for Lyell Immunopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Lyell Immunopharma, Inc. (LYEL).